DHEA for Women: Benefits, Uses, and What the Evidence Actually Shows

Beyond vaginal use: a science-based guide to DHEA in midlife

DHEA is often described as an “anti-aging hormone,” an androgen, or an alternative to estrogen. None of those descriptions quite captures what makes it biologically interesting.

Dehydroepiandrosterone (DHEA) is primarily a steroid precursor. Rather than functioning only as a finished hormone itself, DHEA can be converted by steroid-metabolizing enzymes into downstream androgens and estrogens, including androstenedione, testosterone, dihydrotestosterone (DHT), estrone and estradiol.

Which conversions occur—and how much active hormone is produced—depend partly on the enzymes present in the tissue receiving DHEA.

This local production of active hormones from circulating precursors is often described as intracrinology. It means that tissues can participate in generating their own sex-steroid environment instead of depending exclusively on hormones secreted directly into the bloodstream. [1–3]

But there is an important consequence:

There is no single biological intervention called simply “DHEA.”

A 50 mg oral dose, a 6.5 mg vaginal dose and DHEA applied directly to external vulvar tissue are not interchangeable treatments. They differ in:

dose;
route of administration;
formulation and absorption;
the tissue exposed first;
local versus systemic concentrations;
downstream conversion into androgens and estrogens;
duration of exposure; and
the hormonal state of the woman receiving it.

Even the number of milligrams cannot be interpreted independently of route. Six milligrams placed directly on a target tissue is not pharmacologically equivalent to six milligrams swallowed.

Throughout the DHEA literature, two questions therefore need to accompany almost every claim:

How much DHEA was used—and where was it delivered?

DHEA falls substantially with age

DHEA and its sulfated form, DHEA-S, are produced predominantly by the adrenal glands. Levels rise during adolescence, peak in early adulthood and then decline progressively across adult life.

This trajectory differs from the relatively abrupt loss of ovarian estradiol around menopause.

By the time many women reach menopause, DHEA has already fallen substantially from young-adult concentrations. In classic population data, average serum DHEA concentrations in women aged 50–60 were approximately 70% below those measured at ages 20–30. [1]

This distinction matters because a woman entering midlife is experiencing several overlapping endocrine changes, not simply estrogen loss.

These include:

declining and increasingly erratic ovarian progesterone during perimenopause;
changing ovarian estradiol production;
changes in ovarian androgen production;
and a much longer, age-related decline in adrenal DHEA and DHEA-S.

DHEA decline is therefore an aging phenomenon that overlaps menopause, rather than a consequence of menopause alone.

And the decline itself does not prove that replacing DHEA will restore youthful physiology.

That question can only be answered by studying specific doses, routes and outcomes.

What does DHEA actually do?

DHEA sits upstream from more potent sex steroids.

Depending on the enzymatic machinery within a tissue, DHEA can enter pathways that generate:

DHEA → androstenedione → testosterone → DHT

DHEA → androstenedione → estrone → estradiol

The relative importance of these pathways differs between tissues. [2,3]

This helps explain why circulating estradiol or testosterone concentrations do not necessarily describe the complete sex-steroid environment inside every tissue.

It also explains why DHEA is different from simply administering estradiol or testosterone.

With estradiol, the administered molecule is already an active estrogen.

With testosterone, the administered molecule is already an active androgen.

With DHEA, the tissue participates in determining what comes next.

But this should not be interpreted to mean that DHEA stays exclusively inside the tissue where it is used.

“Intracrine” does not mean “non-systemic.”

How much DHEA and its metabolites enter circulation depends heavily on route, dose and formulation.

Oral DHEA produces substantial systemic exposure.

Vaginal prasterone produces much smaller systemic changes at the approved dose.

External vulvar DHEA has not yet been studied sufficiently to define its pharmacokinetics across doses and formulations with the same confidence.

Dose and route determine what “DHEA treatment” actually means

This is perhaps the most important principle for understanding DHEA research.

Studies frequently get discussed as though researchers simply tested “DHEA.”

In reality, they may have tested entirely different pharmacologic exposures.

Oral DHEA

Many clinical studies in postmenopausal and older women have used 25–50 mg per day, with 50 mg/day particularly common.

After oral administration, DHEA enters systemic circulation and undergoes metabolism throughout the body.

At commonly studied doses, oral DHEA reliably raises circulating DHEA-S and can also increase circulating testosterone and estradiol. [4]

Therefore, when a study reports a benefit—or no benefit—from 50 mg of oral DHEA, that finding applies most directly to that systemic intervention.

It should not automatically be extrapolated to:

lower oral doses;
vaginal DHEA;
externally applied vulvar DHEA;
or another formulation with different absorption.

Vaginal prasterone

Prescription vaginal prasterone provides one of the best-studied examples of locally delivered DHEA.

The FDA-approved dose is 6.5 mg inserted vaginally once daily.

That is dramatically lower than the 25–50 mg oral doses frequently used in systemic studies, and it is delivered directly to vaginal tissue rather than first passing through the gastrointestinal tract and systemic circulation.

Clinical trials demonstrate improvement in:

vaginal epithelial maturation;
vaginal pH;
and moderate-to-severe dyspareunia associated with menopausal vulvovaginal atrophy. [5]

Systemic exposure is limited rather than absent. Small increases in circulating DHEA metabolites, testosterone and estradiol can occur.

The pharmacology therefore differs substantially from 50 mg of oral DHEA.

External vulvar and vestibular DHEA

External vulvar application represents another route again.

The vulva and vestibule are not simply extensions of the vagina.

They differ in:

epithelial structure;
keratinization;
vascularity;
glandular composition;
receptor distribution;
and likely permeability.

The vestibule in particular is embryologically and biologically distinct from adjacent vulvar skin.

Applying DHEA directly to these tissues therefore creates a different exposure than either swallowing DHEA or placing it high within the vagina.

The relevant questions become:

How much reaches vulvar and vestibular tissue?

How much is converted locally?

How much enters systemic circulation?

How does dose change those relationships?

Those questions have not yet been answered with the same depth of pharmacokinetic and clinical research available for vaginal prasterone.

This is why oral, vaginal and external vulvar DHEA studies should not be treated as interchangeable evidence.

Formulation matters too

Route and dose are not the only variables.

A labeled dose tells us how much DHEA is present in a product. It does not necessarily tell us how much reaches the target tissue.

Absorption can also be influenced by formulation.

A DHEA dose delivered in:

a conventional cream;
an oil;
a vaginal suppository;
an emulsion;
a phospholipid-based formulation;
or another enhanced-delivery system

may not create identical tissue exposure.

The same nominal milligram dose can therefore produce different effective concentrations depending on the vehicle and tissue barrier.

For DHEA, the more accurate concept is:

dose × route × formulation × tissue = exposure

That exposure—not merely the number printed on a label—is what ultimately drives pharmacology.

What happens when DHEA is taken orally?

Because much of the whole-body DHEA literature uses oral doses of approximately 25–50 mg/day, the evidence below should be understood primarily as evidence about systemic oral supplementation at those doses.

It should not be assumed to describe low-dose local genital use.

Bone: one of the more credible systemic signals

Of the proposed systemic benefits of DHEA in older women, bone is one of the areas with the more reproducible positive signal.

A pooled analysis of four randomized trials involving 295 women aged 55 and older found that DHEA treatment increased lumbar-spine bone mineral density by approximately 1% over 12 months, produced a smaller increase at the trochanter and appeared to help maintain total-hip BMD. [4]

These effects were seen primarily in women rather than men.

Other systematic reviews and meta-analyses have also identified small improvements at selected skeletal sites. [6]

But several qualifications are important.

First, most of these studies evaluated systemic oral DHEA, commonly around 50 mg/day.

Second, the magnitude of the BMD effect was modest.

Third, increased BMD is not the same as demonstrated fracture reduction.

And fourth, it is not established that a much lower dose—or a predominantly local genital exposure—would reproduce the same skeletal effect.

So the evidence supports a more precise statement:

Systemic oral DHEA at studied doses may modestly improve bone density in older women, but DHEA is not an established osteoporosis therapy.

It should not replace evaluation of:

resistance exercise;
adequate protein and essential amino acids;
calcium and vitamin D status;
estrogen status;
secondary causes of bone loss;
or osteoporosis medication when clinically indicated.

Muscle and body composition: biologically plausible, clinically inconsistent

Because DHEA can increase downstream androgen exposure, it has been studied for muscle strength, lean mass and physical function.

The results are inconsistent.

A systematic review of DHEA trials in older adults found occasional improvements in individual measures of strength but approximately as many negative studies, with little consistent effect on physical performance. [7]

Some studies suggest that DHEA may have greater effects when combined with exercise or in frail individuals. For example, one randomized trial combining DHEA with exercise in frail older women reported improvements in lower-extremity strength and physical performance. [8]

But this evidence should again be interpreted as evidence about the specific systemic doses used.

It does not establish that all DHEA exposures preserve muscle.

Nor does it make DHEA a substitute for the interventions with substantially stronger evidence:

adequate total protein, sufficient essential amino acids—particularly leucine exposure—and progressive resistance training.

Sexual function: dose, route and tissue matter enormously

This is one of the areas where broad statements about DHEA become especially misleading.

DHEA participates in androgen and estrogen physiology, so it is reasonable to ask whether restoring DHEA improves libido.

Yet trials of systemic oral DHEA have produced inconsistent results.

A 52-week randomized trial of postmenopausal women with low libido found that 50 mg/day of oral DHEA did not significantly improve sexual function, well-being or menopause-related quality of life compared with placebo. [9]

Systematic reviews of systemic DHEA have similarly failed to demonstrate a robust effect on sexual function in otherwise healthy postmenopausal women with normal adrenal function. [10]

But that finding answers a specific question:

Does a relatively high systemic oral dose reliably improve sexual function?

It does not answer:

Can DHEA delivered directly to genital tissue improve genital tissue function?

Those are different interventions and potentially different biological mechanisms.

Sexual function itself also contains multiple dimensions.

Desire arising centrally in the brain is not the same endpoint as:

genital sensation;
tissue elasticity;
lubrication;
vestibular comfort;
clitoral responsiveness;
or pain at the vaginal opening.

A treatment can fail to increase generalized libido while still improving the physical capacity for comfortable and pleasurable sexual activity.

Read: DHEA and Libido: The Connection Between Hormones and Sexual Desire

Cognition and brain health: mechanistically interesting, clinically unproven

DHEA and DHEA-S have neurobiological effects and interact with several signaling systems in the central nervous system.

That has generated longstanding interest in DHEA as a possible intervention for cognitive aging.

But clinical evidence has not established a meaningful cognitive benefit.

A systematic review of randomized trials in postmenopausal women found no convincing evidence that DHEA supplementation improves cognitive performance. [11]

Likewise, the year-long DAWN randomized trial found no meaningful benefit of 50 mg/day oral DHEA on cognition, psychological well-being or quality of life in healthy older adults. [12]

Again, the scientifically appropriate conclusion is specific:

Systemic oral DHEA at the doses studied has not demonstrated a consistent cognitive benefit in healthy older adults.

That does not prove that every dose, route or population will have identical neurobiological effects.

But it does mean that DHEA should not currently be promoted as an evidence-based treatment for cognitive decline.

Mood, energy and general well-being

DHEA has also been studied for mood, fatigue and general well-being.

Positive findings have been reported in selected populations, particularly individuals with adrenal insufficiency, where endogenous DHEA production may be markedly reduced.

But trials in otherwise healthy older or postmenopausal women have been much less convincing. [10,13]

This illustrates another major problem in translating DHEA research:

Baseline endocrine state matters.

Replacing DHEA in someone with pathologically low adrenal production is biologically different from increasing DHEA in a healthy person experiencing the normal age-associated decline.

The same dose can therefore represent:

physiologic replacement in one individual;
pharmacologic supplementation in another.

This is one reason a universal “ideal DHEA dose” is unlikely to make biological sense.

Vaginal DHEA has a different evidence base

The strongest clinical evidence for genital DHEA currently comes from intravaginal prasterone.

The FDA-approved 6.5 mg vaginal insert is indicated for moderate-to-severe dyspareunia associated with vulvar and vaginal atrophy due to menopause.

Randomized trials demonstrate changes consistent with improved estrogenic support of vaginal tissue, including:

increased superficial epithelial cells;
reduced parabasal cells;
reduced vaginal pH;
and improved pain with sexual activity. [5]

The important point is not simply that “DHEA worked.”

The intervention was:

6.5 mg DHEA + vaginal route + vaginal tissue + daily dosing

That combination produced the observed result.

Changing any of those variables may change the outcome.

What about the vulva and vestibule?

This is where an important gap remains.

Many women experience menopausal genital symptoms not simply “inside the vagina,” but at the:

vestibule;
introitus;
labia minora;
clitoral structures;
and other external vulvar tissues.

The vestibule is also a major site of provoked pain in many women with dyspareunia.

These tissues contain androgen and estrogen receptors and steroid-metabolizing enzymes capable of participating in local hormone biology.

That creates a compelling mechanistic rationale for studying DHEA directly at the site of symptoms.

But mechanistic plausibility is not the same as completed clinical evidence.

We still need better data defining:

external vulvar absorption;
vestibular tissue concentrations;
dose-response relationships;
systemic exposure;
optimal formulation;
symptom response;
histologic effects;
and long-term safety.

The vaginal prasterone literature provides useful biological context, but it cannot by itself establish the pharmacology of external vulvar application.

Read our detailed evidence review: DHEA and Vulvar Tissue: What It Is, How It Works, and What the Evidence Shows

Is DHEA estrogen or testosterone?

Neither.

DHEA is a precursor capable of contributing to the production of both.

That distinction is important.

It means DHEA does not behave exactly like administering estradiol.

It does not behave exactly like administering testosterone.

But calling DHEA a precursor should not be confused with calling it hormonally inactive.

At sufficient systemic doses, oral DHEA can increase circulating:

DHEA-S;
testosterone;
and estradiol. [4]

Vaginal prasterone can produce smaller measurable changes in circulating downstream steroids. [5]

The degree to which this occurs depends substantially on dose and route.

Is locally applied DHEA “non-systemic”?

That description is too absolute.

A more scientifically accurate distinction is between predominantly local exposure and substantial systemic exposure.

No biological barrier is necessarily perfect.

A compound placed on or within genital tissue may undergo:

local absorption;
local metabolism;
local receptor activity;
entry into venous or lymphatic circulation;
and subsequent systemic metabolism.

How much follows each pathway depends on:

dose × formulation × route × tissue

Vaginal prasterone provides an example: it is designed for local genital use and produces much lower systemic exposure than commonly studied oral doses, but systemic changes are not literally zero.

For external vulvar DHEA, this relationship still needs to be defined experimentally.

Can DHEA cause side effects?

Yes.

The likelihood and type of side effect also depend on dose and systemic exposure.

With systemic oral DHEA, androgenic effects reported in clinical studies include:

acne;
oily skin;
increased facial or body hair;
and other androgen-related changes.

In the randomized trial using 50 mg/day oral DHEA, acne and increased hair growth occurred more frequently in women receiving DHEA than placebo. [9]

Because DHEA can contribute to both androgen and estrogen synthesis, changing DHEA exposure may also be clinically relevant in individuals with:

hormone-sensitive cancers;
unexplained vaginal bleeding;
significant androgen-sensitive symptoms;
or other conditions in which changes in sex-steroid exposure warrant caution.

The fact that oral DHEA is sold over the counter in the United States does not mean that every dose, route or formulation is biologically trivial.

So should women take DHEA in midlife?

There is no universal answer.

More importantly, the question itself is incomplete.

The scientifically meaningful question is:

Which dose of DHEA, delivered by which route, in which formulation, to which tissue, for which clinical objective?

For oral DHEA, commonly studied systemic doses of approximately 25–50 mg/day clearly alter circulating steroid physiology. Clinical benefits in otherwise healthy midlife and older women are mixed. Bone has one of the more credible positive signals; evidence for cognition, generalized well-being, muscle function and libido is considerably less consistent.

For vaginal prasterone, 6.5 mg/day delivered directly to vaginal tissue has a much stronger and more specific evidence base for menopausal vaginal tissue changes and dyspareunia, with relatively limited systemic exposure.

For external vulvar and vestibular DHEA, the biology is compelling and directly relevant to tissues that are often symptomatic, but clinical pharmacokinetic and outcomes research remains comparatively limited.

These are not contradictory findings.

They are evidence that DHEA behaves differently when we change the exposure.

A 50 mg oral dose that fails to improve generalized sexual desire does not tell us whether a much smaller quantity delivered directly to androgen-responsive genital tissue can improve tissue function.

Likewise, successful treatment of vaginal tissue with 6.5 mg intravaginal prasterone does not automatically establish the optimal dose, exposure or clinical effect of external vulvar application.

That is the essential point.

There may be no scientifically meaningful answer to “Does DHEA work?” until we specify how much DHEA, delivered where, and for what purpose.

And because DHEA is a precursor rather than a single end-stage hormone, these distinctions may matter even more than they do for conventional hormone replacement.

Frequently Asked Questions

What is the difference between DHEA and DHEA-S?

DHEA-S is the sulfated form of DHEA and circulates in blood at much higher concentrations. It serves as a large circulating reservoir from which DHEA and downstream sex steroids can ultimately be generated.

Does DHEA increase testosterone in women?

It can.

Systemic oral DHEA, particularly at commonly studied doses such as 25–50 mg/day, can increase circulating testosterone.

The magnitude depends on dose, route, metabolism, age and baseline endocrine status.

That does not mean every low-dose or locally delivered DHEA preparation produces the same systemic increase.

Does DHEA increase estrogen?

It can.

DHEA can be converted through steroidogenic pathways into estrone and estradiol.

Oral DHEA at systemic doses has increased circulating estradiol in randomized trials.

Vaginal prasterone produces much smaller systemic changes.

Again, the answer depends on how much DHEA is delivered and by which route.

Is 5 mg of DHEA the same whether swallowed or applied locally?

No.

Milligrams describe the amount of compound administered, not the exposure produced in each tissue.

A 5 mg oral dose and a 5 mg topical dose can differ substantially in:

absorption;
metabolism;
local concentration;
peak systemic concentration;
and downstream hormone production.

Dose cannot be interpreted independently of route and formulation.

Is DHEA good for menopause?

That question encompasses several different interventions.

Oral DHEA has not consistently improved broad menopausal symptoms or quality of life in otherwise healthy women.

Vaginal prasterone, however, has demonstrated efficacy for menopausal dyspareunia and vaginal tissue changes.

External vulvar DHEA is a separate route for which the evidence base is still developing.

Does DHEA improve libido?

Not reliably when studied as a relatively high-dose oral systemic supplement in otherwise healthy postmenopausal women.

That does not rule out effects of DHEA delivered directly to genital tissue, because sexual desire and genital tissue function are not the same endpoint and the pharmacology of local delivery differs substantially from oral supplementation.

Does DHEA help bone density?

Systemic oral DHEA at studied doses may produce modest improvements in BMD in older women.

Whether substantially lower systemic exposure or local genital administration has meaningful skeletal effects is not established.

Does topical DHEA stay completely local?

That should not be assumed.

Local application can preferentially expose the tissue where DHEA is placed, but some systemic absorption may occur.

The amount depends on dose, formulation, tissue and route.

For external vulvar use specifically, better human pharmacokinetic data are still needed.

Last reviewed: August 2026

Educational Note

The information on this page is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any medical condition.

By Laura Kelly, DAOM, L.Ac., Dipl. O.M. A California-licensed primary care provider and nationally board-certified clinician with a clinical focus on women’s health and healthy aging. Research Scholar, Ronin Institute. ORCID: 0000-0001-6586-7308. More about Dr. Kelly

References

Labrie F, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997;82:2396–2402.
Labrie F. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol. 2001.
Labrie F, et al. Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology. J Steroid Biochem Mol Biol. 2017;168:9–18.
Jankowski CM, et al. Sex-specific effects of dehydroepiandrosterone on bone mineral density and body composition: a pooled analysis of four clinical trials. Clin Endocrinol (Oxf). 2019;90:293–300.
INTRAROSA® (prasterone) vaginal inserts. U.S. Prescribing Information.
Lin H, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA supplementation on bone mineral density in healthy adults. Gynecol Endocrinol. 2019.
Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. J Am Geriatr Soc. 2011;59:997–1002.
Kenny AM, et al. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc. 2010.
Panjari M, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009;6:2579–2590.
Elraiyah T, et al. The benefits and harms of systemic dehydroepiandrosterone in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014.
Sultana F, Davis SR, Islam RM. Effect of dehydroepiandrosterone therapy on cognitive performance among postmenopausal women: a systematic review of randomized clinical trial data. Menopause. 2023;30:1167–1173.
von Mühlen D, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DAWN Trial. J Am Geriatr Soc. 2008.
Gurnell EM, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008.

Cart 0

Sorry, looks like we don't have enough of this product.

DHEA Benefits for Women: Beyond Vaginal Use